P Roy Vagelos is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 312,578 shares of REGN, which is worth approximately $223 Million. The most recent transaction as insider was on Mar 23, 2023, when has been sold 25,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 313K
0% 3M change
0% 12M change
Total Value Held $223 Million

P ROY VAGELOS Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 23 2023
SELL
Bona fide gift
-
25,000 Reduced 7.41%
312,578 Common Stock
Feb 22 2023
SELL
Payment of exercise price or tax liability
$21,758,390 $750.16 p/Share
29,005 Reduced 7.91%
337,578 Common Stock
Feb 22 2023
BUY
Exercise of conversion of derivative security
$11,493,275 $270.43 p/Share
42,500 Added 10.39%
366,583 Common Stock
Dec 16 2022
BUY
Grant, award, or other acquisition
-
1,651 Added 0.51%
324,083 Common Stock
Dec 09 2022
SELL
Payment of exercise price or tax liability
$42,936 $753.28 p/Share
57 Reduced 0.02%
322,432 Common Stock
May 24 2022
SELL
Bona fide gift
-
23,077 Reduced 6.68%
322,489 Common Stock
Mar 14 2022
SELL
Payment of exercise price or tax liability
$31,521,414 $655.29 p/Share
48,103 Reduced 12.22%
345,566 Common Stock
Mar 14 2022
BUY
Exercise of conversion of derivative security
$13,434,750 $179.13 p/Share
75,000 Added 16.0%
393,669 Common Stock
Dec 08 2021
BUY
Grant, award, or other acquisition
-
1,861 Added 0.58%
318,669 Common Stock
Aug 25 2021
SELL
Payment of exercise price or tax liability
$32,890,315 $667.39 p/Share
49,282 Reduced 13.46%
316,808 Common Stock
Aug 25 2021
BUY
Exercise of conversion of derivative security
$13,434,750 $179.13 p/Share
75,000 Added 17.0%
366,090 Common Stock
Aug 09 2021
SELL
Bona fide gift
-
17,000 Reduced 5.52%
291,090 Common Stock
Jun 14 2021
SELL
Bona fide gift
-
19,000 Reduced 5.81%
308,090 Common Stock
May 27 2021
SELL
Bona fide gift
-
22,000 Reduced 6.3%
327,090 Common Stock
Feb 23 2021
SELL
Payment of exercise price or tax liability
$63,269,325 $458.48 p/Share
137,998 Reduced 28.33%
349,090 Common Stock
Feb 23 2021
BUY
Exercise of conversion of derivative security
$13,007,500 $52.03 p/Share
250,000 Added 33.92%
487,088 Common Stock
Dec 09 2020
BUY
Grant, award, or other acquisition
-
2,439 Added 1.02%
237,088 Common Stock
PRV

P Roy Vagelos

Director
Tarrytown, NY

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Track Activities on REGN